Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
Annovis Bio Inc. (NYSE: ANVS) has achieved critical milestones in its Alzheimer's disease treatment development, with full activation of all 84 clinical trial sites for its pivotal Phase 3 study and promising biomarker data indicating strong therapeutic potential. The late-stage clinical drug platform company reported significant third quarter 2025 progress, highlighting steady enrollment across the United States for its Alzheimer's trial (NCT06709014) as it moves toward completion.
The company announced compelling biomarker data from its Phase 2/3 Alzheimer's trial demonstrating substantial reductions in both inflammation and neurodegeneration markers. These findings underscore buntanetap's disease-modifying capabilities, suggesting the treatment may address underlying pathological processes rather than merely managing symptoms. The biomarker results provide scientific validation for the drug's mechanism of action as the company advances toward key data readouts.
Recent corporate achievements include the strategic transfer of all patents covering the new crystal form of buntanetap, securing intellectual property protection through 2046. This extended IP protection provides long-term commercial exclusivity for the potential treatment. Additionally, the company has published supportive pharmacokinetic data and strengthened its leadership team with the appointment of veteran finance executive Mark Guerin as Chief Financial Officer.
Maria Maccecchini, Ph.D., president and CEO of Annovis Bio, emphasized the company's readiness for upcoming milestones, stating that every element is now aligned as they move toward data readouts. These results represent the final step before submitting a New Drug Application to regulatory authorities. The company's progress can be tracked through its corporate communications at https://www.annovisbio.com and investor updates available at https://ibn.fm/ANVS.
The advancement of Annovis Bio's Alzheimer's program comes at a critical time for neurodegenerative disease treatment, with growing recognition that effective therapies must address multiple pathological pathways simultaneously. The company's approach with buntanetap represents a potentially significant advancement in treating Alzheimer's disease, which affects millions of patients worldwide and represents one of the largest unmet medical needs in neurology.